A longitudinal study on an autoimmune murine model of ankylosing spondylitis

T Bárds, Z Szabó, M Czipri, C Vermes, M Tunyogi-Csapó, R M Urban, K Mikecz, T T Glant

Background: Proteoglycan aggrecan (PG)-induced arthritis (PGIA) is the only systemic autoimmune murine model which affects the axial skeleton, but no studies have been performed characterising the progression of spine involvement.

Objectives: To follow pathological events in experimental spondylitis, and underline its clinical, radiographic, and histological similarities to human ankylosing spondylitis (AS), and to determine whether the spondyloarthropathy is a shared phenomenon with PGIA, or an "independent" disease.

Methods: Arthritis/spondylitis susceptible BALB/c and resistant DBA/2 mice, and their F1 and F2 hybrids were immunised with cartilage PG, and radiographic and histological studies were performed before onset and weekly during the progression of spondylitis.

Results: About 70% of the PG immunised BALB/c mice develop spondyloarthropathy (proteoglycan-induced spondylitis (PGISp)), and the progression of the disease is very similar to human AS. It begins with inflammation in the sacroiliac joints and with enthesitis, and then progresses upwards, affecting multiple intervertebral disks. In F2 hybrids of arthritis/spondylitis susceptible BALB/c and resistant DBA/2 mouse the incidence of arthritis was 43.5%, whereas the incidence of spondylitis was >60%. Some arthritic F2 hybrid mice had no spondylitis, whereas others developed spondylitis in the absence of peripheral arthritis.

Conclusions: The PGISp model provides a valuable tool for studying autoimmune reactions in spondylitis, and identifying genetic loci associated with spondyloarthropathy.

Materials and Methods

Antigens, animals, experimental groups, and immunisation

The use of human cartilage from joint replacement operations for antigen isolation was approved by the Institutional Review Board, and all animal experiments were approved by the Institutional Animal Care and Use Committee. Human cartilage PG was used for immunisation of 24–26 week old female BALB/c mice purchased from the National Cancer Institute (NCI, Kingston Colony, NY). Preparation of cartilage PG was carried out as described earlier. As a standard method, the first antigen injection (100 µg PG protein) was given in complete Freund's adjuvant (Difco, Detroit, MI), and the same doses of antigen were injected as second and third boosts in incomplete Freund's adjuvant on weeks 3 and 6 (n = 210). Control female BALB/c mice matched for age were either not immunised (n = 75) or immunised with ovalbumin, a non-cartilage-related antigen in adjuvant (n = 75). A small group of PG immunised male mice (n = 12) was used as a positive control, and ovalbumin plus adjuvant injected BALB/c male mice (n = 8) as a negative control group, and all were killed at the end of the experiments at week 36 (fig 1).

In a second set of experiments, arthritis and spondylitis susceptible BALB/c female mice were mated with arthritis resistant DBA/2 male mice and the resulting F1 offspring were mated to generate F2 hybrids. These F2

Abbreviations: AS, ankylosing spondylitis; IVD, intervertebral disk; PG, proteoglycan aggrecan; PGIA, PG-induced arthritis; PGISp, PG-induced spondylitis; SpA, spondyloarthropathy
Intercrosses were also immunised with cartilage PG as described above. A total of 210 female BALB/c mice were immunised with human cartilage (PGIA; thick black arrow) and spondylitis (PGISp; thick white arrow). A score of 4 for each paw was used for the assessment of clinical symptoms of arthritis. A standard scoring system, spondylitis; clinical and histological assessments of arthritis and spondylitis in cartilage PG immunised mice

Figure 1 Time course of immunisation, number of animals killed and analysed weekly, and the time of onset of arthritis in peripheral joints (PGIA; thick black arrow) and spondylitis (PGISp; thick white arrow). A total of 210 female BALB/c mice were immunised with human cartilage PG in the first experimental group, and five killed weekly.

(36 female mice and 12 male mice) and all F2 hybrids (106 female mice and 117 male mice) of BALB/c × DBA/2 intercrosses were also immunised with cartilage PG as described above. Clinical and histological assessments of arthritis and spondylitis

Immunised BALB/c mice were examined twice a week for clinical symptoms of arthritis. A standard scoring system, based upon swelling and redness of each paw (a maximum score of 4 for each paw) was used for the assessment of arthritis. During the first 6 weeks of immunisation (until the third injection), we killed five immunised mice every week. During the next 5 weeks, as arthritic mice became available (fig 1; inductive phase of arthritis), we killed five immunised mice every week (fig 1). From week 12 (that is, 6 weeks after the third injection), when eventually all PG aggrecan immunised BALB/c mice were arthritic, except for three female mice (table 1), we killed five mice weekly until week 26, and then 20 arthritic mice were killed at week 30. The remaining 32 arthritic and three non-arthritic PG immunised female mice, and all male mice, were killed on the last day (week 36) of the experimental period (fig 1).

In the second set of experiments, PG immunised BALB/c (n = 81), DBA/2 (n = 48), and their F1 (n = 48) and F2 (n = 223) hybrid offspring were scored weekly, and onset and severity of arthritis were recorded as described above for BALB/c mice. Animals were killed on week 30 and disease onset and severity were correlated with the final histological score of the spine.

A histology scoring system was established for the severity of spine involvement: score 1, enthesitis, inflammatory cell accumulation around the IVD and/or infiltration of the annulus fibrosus; score 2, <50% absorption/erosion of the IVD; score 3, essentially complete resorption (>50%) of the IVD; score 4, cartilaginous/bony ankylosis. A minimum of 18–22 IVDs (from the distal cervical to the lumbar regions) of each control and immunised mouse was scored. Finally, the spondylitis score of each animal was calculated by dividing the total score (all IVD scores) by the number of IVDs examined histologically. Autoimmune reactions (antibody production and T cell responses) to immunising human and mouse (self) PGs were determined as described previously.

RESULTS

Development of peripheral arthritis, and PG-specific antibody and T cell responses

As described earlier and above (experimental groups), most of the PG immunised BALB/c mice developed peripheral arthritis between days 7 and 14 after the third antigen injection (table 1). All arthritic mice showed strong humoral and cellular immune responses to PG, as described in detail in our earlier papers. In this respect, we found no differences between mice with and without spine involvement, and no correlation between the severity of spondylitis and PG-specific antibody levels. In a similar way to that described above for antibody responses, T cell reactions in PG immunised BALB/c mice with and without spondylitis were highly comparable, and neither PG-specific antibodies nor T cell responses were detected in non-immunised or ovalbumin/adjuvant immunised mice.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Incidence of arthritis and spondylitis in cartilage PG immunised mice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Week of the experiment</strong></td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><strong>Weeks after the 3rd PG immunisation</strong></td>
<td><strong>0</strong></td>
</tr>
<tr>
<td><strong>Incidence of peripheral arthritis</strong></td>
<td>0/210 (0%)</td>
</tr>
<tr>
<td><strong>Incidence of spondylitis</strong></td>
<td>ND (0%)</td>
</tr>
</tbody>
</table>

*Incidence is expressed as the number of affected/total BALB/c mice (results are also shown as % in parentheses). The last column includes results of the 12 positive control male mice (PGISp incidence 75%), whereas all other animals were female BALB/c mice; †by week 5 after the third PG injection, only three PG immunised mice remained non-arthritic, and these animals were followed up until the end of the experiment. Two of these three non-arthritic BALB/c mice developed spondylitis; ‡calculation is based upon histological analysis of the spine, and positive/total number of killed animals (%) is shown.

www.annrheumdis.com
Histological assessment of spine involvement in PG immunised BALB/c mice

Histological analysis showed axial involvement as early as week 8 after the third PG injection (data not shown). The disease affected only the PG immunised mice, and abnormalities could not be detected in any of the control animals. Cartilage surface erosions were found first in the sacroiliac joints (fig 2B); IVDs of the proximal tail became affected simultaneously with, or shortly after, the development of inflammation in the sacroiliac joint. During the course of the disease, first the lumbar, and later the proximal, thoracic and distal cervical segments became involved, but not all IVDs were equally affected at a particular time. The fibrocartilaginous articular surface of the sacroiliac joints became eroded (fig 2B), which was followed by a focal (fig 2C) and then more extensive (fig 2D) chondrocyte proliferation. This reactive cell proliferation gave rise to chondrophyte-like tissue; the sacroiliac joint was completely ankylosed within 1–2 months after the first arthritis in the peripheral joints. This was followed shortly by massive proliferation of chondrocyte-like cells (white arrowheads in (C), which formed a junction of chondrophytes, resulting in complete ankylosis of the sacroiliac joint (D). The tissue sections were stained with haematoxylin and eosin.

Figure 2

Inflammation of the sacroiliac joints and progression of ankylosis in PG immunised BALB/c mice with spondylitis. The normal sacroiliac joint [A], which is first eroded by a synovial pannus-like hyperproliferative tissue (black arrows) at the articular surfaces indicated with dotted lines in (B), as early as 4–6 weeks after the onset of arthritis in the peripheral joints. This was followed by massive proliferation of chondrocyte-like cells (white arrowheads in (C), which formed a junction of chondrophytes, resulting in complete ankylosis of the sacroiliac joint (D). The tissue sections were stained with haematoxylin and eosin.

Macroscopic analysis of spondylitic spines

For macroscopic examination, spines were stained with alizarin red and alcian blue (fig 4). This staining shows more details of the cartilaginous and bony components of the deformed spine regions. In contrast with the normal disk, where the growth plates and end plates of the vertebral bodies appeared as sharp solid lines (fig 4A), the contours of these cartilaginous tissues became diffuse owing to chondrophyte formation (fig 4B). Progression of spondylitis was seen in each animal that developed spondylitis: the disk space disappeared and a chondrophyte/osteophyte, fusing the neighbouring vertebral bodies, replaced the original IVD (fig 4C).

Analysis of peripheral arthritis and spondylitis in F2(BALB/c × DBA/2) hybrid mice

As described above, three PG immunised BALB/c female mice did not develop PGIA, but two of the three showed SpA at the end of the experiment (table 1). Therefore, we assume that SpA develops independently of arthritis in PG immunised BALB/c mice. To confirm this hypothesis and separate overlapping clinical, histopathological, and laboratory measures of the two diseases, we immunised 223 F2(BALB/c × DBA/2) hybrids, and their parents. All mice (BALB/c, DBA/2, F1 and F2 hybrids) were killed on week 30 of immunisation, as the development of PG-induced spondylitis (PGISp) achieved a constant (~70%) level by week 26 of immunisation (table 1). Figure 5A shows the major characteristics and distribution of peripheral arthritis and spondylitis in these experimental groups. About 40% of the PG immunised F2(BALB/c × DBA/2) mice developed PGIA, but unexpectedly, over 60% had spondylitis. Most of the arthritic mice had spondylitis (85/97), and 52/223 (23.3%) PG immunised F2 hybrids had spondylitis without joint inflammation (fig 5A; right panel).

In this second set of experiments, 81 (63 female and 18 male) BALB/c mice developed PGIA (mean (SD) arthritis score 11.6 (2.4)), which was associated with PGISp (mean (SD) spondylitis score of affected animals 1.45 (0.62)) in 57 (70%) animals.
DISCUSSION

Normal IVD is a complex fibrocartilaginous structure containing poorly defined chondrocyte-like and fibroblast-like cells that can survive in a relatively avascular environment. The extracellular matrix of the IVD contains two major groups of macromolecules: collagens and proteoglycans. Whereas the nucleus pulposus contains almost uniformly aggrecan and type II collagen, the annulus fibrosus is formed mostly by type I collagen fibrils embedded in aggrecan and versican. The insertion site of the ligaments into the cortical bone—that is, the enthesis, also contains proteoglycan, mostly versican, which might be degraded in IVDs undergoing degenerative processes.

The core protein of human cartilage (and nucleus pulposus) PG comprises more than 2300 amino acids, and contains 20–27 T cell epitopes presented to T cells by various major histocompatibility complexes of antigen presenting cells. Most of these epitopes, however, are in a “cryptic” position—that is, masked by glucosaminoglycan side chains. A few T cell epitopes of human PG have been characterised as dominant/arthritogenic, and owing to the high sequence homology between human and mouse PGs, immunisation of susceptible BALB/c and C3H mice with human PG provokes autoimmune responses to mouse (self) PGs, which then induce arthritis and spondylitis.

Spondylodiscitis (a robust form of inflammation affecting the entire IVD) occurs in 15% of patients with AS, but the incidence is greater (up to 60%) when diagnosed by magnetic resonance imaging. The primary site of the inflammation in AS, however, is still debated; it is proposed to be in the subchondrium or in the synovium (sacroiliac joint) close to the entheses.

To date, spontaneous or experimentally induced disk degeneration has been reported only in a few animal models. Autoimmune mechanisms are thought to play a part only in HLA-B27 transgenic rodents and...
in PGIA. As HLA-B27 transgenic animals, when maintained in germ-free conditions, do not develop spondylitis, the molecular mimicry of bacterial antigens may be a strong contributing factor to the pathomechanisms of SpA either in these transgenic rodents or in human patients. Nevertheless, none of these animal models is identical with human AS, but may mimic genetic and/or pathological abnormalities present in the human disease. One example is that, in addition to the major histocompatibility complexes, the major genetic loci of the PGISp in F2 hybrids of BALB/c and DBA/2, and BALB/c and C3H intercrosses are localised on chromosome 2 (authors unpublished observation), which corresponds with that identified in patients with AS. PGIA is characterised by a fine cooperation between antibody producing and antigen presenting B cells and T helper cells, and affects both the axial and peripheral skeleton.

The chronology of pathological events in this model suggests that the involvement of the sacroiliac joint and the spine is similar to AS. PG immunised mice first exhibit strong mononuclear influx and develop pannus-like tissue in the sacroiliac joint. The infiltrated tissue gradually destroys cartilage, which is followed by complete ankylosis of the joint. Simultaneously with, or shortly after, the initial signs of sacroiliitis, spondylitis/spondylodiscitis flares up with mononuclear infiltration around the annulus, followed by destabilisation of the annulus and protrusion of the nucleus. Matrix components from the nucleus could be additional local sources of autoantigens. The abundance of antigens in this environment can initiate self sustaining (auto)immune reactions that ultimately lead to the complete loss of IVD, and reactive chondropyte/osteophyte formation and ankylosis, fusing together vertebral bodies.

**Figure 4** Progression of spondylitis in the lumbar spine (L3-5) in PG immunised BALB/c mice. Alizarin red stains bone red, while alcian blue stains the cartilaginous structures blue. Black arrowheads indicate the cartilaginous growth plates of the vertebral bodies (A; control), which became moderately deformed by 12 weeks (B) and grossly altered by 24 weeks (C) after the onset of peripheral joint inflammation. White arrows show chondrophyte formation at the marginal regions of the vertebral bodies.

**Figure 5** (A) Analysis and comparison of PG-induced arthritis (PGIA: A) and PG-induced spondylitis (PGISp: Sp) in 81 BALB/c (B/c), 48 DBA/2 (D/2) mice and their F1 and F2 hybrids (BALB/c × DBA/2) immunised with human cartilage PG. All mice were injected four times with PG and killed on week 30 of the experiment—that is, 21 weeks after the last immunisation. (B) Significant differences when male mice and female mice with arthritis or spondylitis, or both, were compared: *p<0.05; **p<0.01.
PG is one of the major extracellular matrix proteins located in immunoprevilied sites of the body (such as in the articular cartilage or nucleus pulposus of the IVD), therefore, it might become a target antigen in autoimmune diseases.15-17 Here, we demonstrate that spondylitis develops in arthritis susceptible mice immunised with PG, and the progression of the spine disease resembles that seen in human AS. Therefore, we postulate that PG has an important role in PGISP in this model, and perhaps also has a role in humans with autoimmune SpA.13-14 15 16 As far as we know, this is the first time that a systematic and longitudinal study has been performed on spine disease in mice with systemic inflammation using a cartilage protein (cartilage PG). We found that spondylitis developed without arthritis, especially in PG immunised F2 hybrids of PGIA susceptible BALB/c and resistant DBA/2 strains. Vice versa, about 30% of arthritic mice did not show evidence of spondylitis. These observations strongly suggest that PGIA and PGISP are independent diseases, although immunisation with cartilage PG is an absolute requirement for the induction of either PGIA or PGISP.

In conclusion, it is very likely that there are both overlapping/shared and distinct genetic components of the (auto)immune regulation in these two models. Although the autoimmune pathomechanisms of PGIA and PGISP seem to be similar, the incidence, severity, and particularly the genetic control of joint and spine involvement are likely to be distinct. Using F2 hybrids of arthritis and spondylitis-resistant DBA/2 and susceptible BALB/c mice, we showed a maximum of 57% (85/149 affected animals) overlap between PGIA and PGISP, whereas 40% of the F2 hybrid mice with spondylitis did not have arthritis. Therefore, this report supports the relevance of performing genome-wide screening studies for identification of susceptibility loci controlling AS in this experimental murine model, which seems to mimic the human disease.

ACKNOWLEDGEMENTS
This work was supported, in part, by grants (AR40310, AR45652, AR51163) from the National Institute of Health (USA).

Authors’ affiliations
T Bárdos, Z Szabó, M Czipri, C Vermes, M Tunyogi-Csapó, R M Urban, K Mikecz, T T Glant, Department of Molecular Medicine, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA T Bárdos, M Czipri, C Vermes, M Tunyogi-Csapó, Department of Orthopaedic Surgery, University of Pécs, Pécs, Hungary Z Szabó, Department of Internal Medicine 3, University of Debrecen, Hungary K Mikecz, T T Glant, Department of Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA K Mikecz, Immunology/Microbiology, Rush University Medical Center, Chicago, IL 60612, USA T T Glant, Internal Medicine (Section of Rheumatology), Rush University Medical Center, Chicago, IL 60612, USA

REFERENCES
A murine model of ankylosing spondylitis


